HIV/AIDS Clinical Trials in Los Angeles

Showing 101-120 of 290 trials

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

NCT01928927

The main goal of this study was to see if a drug called telmisartan would decrease fibrosis (scarring) and inflammation (irritation) in people who are infected with HIV and doing well on their HIV medications. The study was also done to see what effects telmisartan has on other signs of disease and inflammation in the body, and to see whether people who have HIV can take telmisartan safely and without side effects that make them want to stop the drug. Telmisartan is FDA-approved for treating high blood pressure and decreasing the chance of heart attacks and strokes in people over the age of 55 years of age who are at high risk for these events.

HIV-1 Infection

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections58 participantsStarted Jan 2014

Los Angeles, California, United States • Aurora, Colorado, United States • Boston, Massachusetts, United States +9 more locations

COMPLETEDPHASE1/PHASE2< 1 mile

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

NCT01543152

The purpose of the study is to evaluate the safety, tolerability and effect on HIV viral load, of escalating doses of cyclophosphamide administered 1 day prior to SB-728-T infusion.

HIV

Sangamo Therapeutics26 participantsStarted Dec 2011

Los Angeles, California, United States • San Francisco, California, United States • Norwalk, Connecticut, United States +8 more locations

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

HIV/AIDS Trials in Other Cities

CCTG 593: Testing and Linkage to Care

Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

Improving Engagement in HIV Care for High-risk Women

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

Depression Intervention Among Gay and Bisexual Men Receiving Treatment for Methamphetamine Use

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

Using Mobile Technology and Incentives With Men Who Have Sex With Men and Transgender Women for HIV Prevention

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

Preventing Frequent Sinus Infections in HIV-Infected Patients

Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

Other Conditions in Los Angeles